- Home
- CNF vs PYPD Comparison
CNF vs PYPD Comparison
Compare CNF & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- PYPD
- Stock Information
- Founded
- CNF 1999
- PYPD 2008
- Country
- CNF China
- PYPD Israel
- Employees
- CNF N/A
- PYPD N/A
- Industry
- CNF Finance: Consumer Services
- PYPD Medical/Dental Instruments
- Sector
- CNF Finance
- PYPD Health Care
- Exchange
- CNF Nasdaq
- PYPD Nasdaq
- Market Cap
- CNF 35.7M
- PYPD 34.8M
- IPO Year
- CNF 2018
- PYPD 2020
- Fundamental
- Price
- CNF $4.27
- PYPD $3.36
- Analyst Decision
- CNF
- PYPD Strong Buy
- Analyst Count
- CNF 0
- PYPD 5
- Target Price
- CNF N/A
- PYPD $12.00
- AVG Volume (30 Days)
- CNF 63.1K
- PYPD 49.6K
- Earning Date
- CNF 08-28-2025
- PYPD 11-12-2025
- Dividend Yield
- CNF N/A
- PYPD N/A
- EPS Growth
- CNF N/A
- PYPD N/A
- EPS
- CNF N/A
- PYPD N/A
- Revenue
- CNF $50,241,013.00
- PYPD N/A
- Revenue This Year
- CNF $252.34
- PYPD N/A
- Revenue Next Year
- CNF N/A
- PYPD N/A
- P/E Ratio
- CNF N/A
- PYPD N/A
- Revenue Growth
- CNF N/A
- PYPD N/A
- 52 Week Low
- CNF $2.36
- PYPD $2.30
- 52 Week High
- CNF $20.00
- PYPD $3.93
- Technical
- Relative Strength Index (RSI)
- CNF 52.57
- PYPD 46.62
- Support Level
- CNF $2.85
- PYPD $3.25
- Resistance Level
- CNF $4.26
- PYPD $3.57
- Average True Range (ATR)
- CNF 0.47
- PYPD 0.13
- MACD
- CNF -0.05
- PYPD 0.00
- Stochastic Oscillator
- CNF 64.07
- PYPD 34.37
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.